Mladen Paradžik

Mladen Paradžik is a Researcher at the Ruđer Bošković Institute, affiliated with the Division of Molecular Medicine and Laboratory of Experimental Therapy in Zagreb, Croatia. His work focuses on cancer biology, molecular signaling, and cell adhesion mechanisms.

• PhD in Biology, University of Zagreb (2015)
• BSc in Biology, University of Zagreb (2008)

Research interests span integrin signaling, miRNA-guided metabolic reprogramming, and Sirtuin 3 (Sirt3) tumor-suppressive mechanisms. He investigates how cytoskeletal components like KANK2 and integrin αVβ5 regulate cancer cell migration and chemotherapeutic sensitivity.

Recent publications highlight trends in integrin adhesomes (2023-2018), miRNA-tumor progression (2022-2021), and Sirt3-p53-estrogen pathways (2020-2018) in breast cancer and melanoma models.

Professional memberships include the Croatian Association for Cancer Research (2010–present), Croatian Immunological Society (2009–present), and Croatian Society of Biochemistry and Molecular Biology (2018–present).

He has contributed to understanding integrin crosstalk in cancer cell fate unpredictability (2020), Golgi apparatus disruption in EMT (2023), and αVβ5 focal adhesion-microtubule coupling (2020). Collaborations span institutions like University of Manchester (UK) and MedILS (Croatia).